BTLA agonist attenuates Th17-driven inflammation in a mouse model of steroid-resistant asthma
Our findings establish BXD75 mice as a model for steroid-resistant asthma and demonstrate that BTLA agonism attenuates airway hyperreactivity and lung inflammation, highlighting it as a potential therapeutic strategy.
Authors
- Pejman Soroosh
- Omid Akbari (ORCID: https://orcid.org/0000-0002-4359-9725)
- Doumet Georges Helou (ORCID: https://orcid.org/0000-0002-5835-9214)
- Benjamin P. Hurrell (ORCID: https://orcid.org/0000-0001-7753-2927)
- Pedram Shafiei-Jahani (ORCID: https://orcid.org/0000-0003-1768-0770)
- Xin Li (ORCID: https://orcid.org/0000-0002-2050-2628)
- Christine Quach (ORCID: https://orcid.org/0000-0003-4802-8013)
- Stephen Shen (ORCID: https://orcid.org/0000-0002-8417-1880)
- Meng Li (ORCID: https://orcid.org/0000-0001-8675-0758)
Institutions
- University of Southern California (US)
- Janssen (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.3389/fimmu.2025.1552394
- Citations
- 3
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.49